ISSN: 1859 - 2872
Primary outcome evaluation of interstitial brachytherapy stage I-III mobile tongue cancer treatment
Main Article Content
Keywords
Abstract
Objective: To survey the optimization of target volume and constraint dose; To estimate the 2-year locoregional control rate after treatment; To evaluate complications of interstitial brachytherapy. Subject and method: A cross-sectional retrospective study 25 patients with mobile tongue cancer stage I, II, and III that have been admitted at Department of Radiation Head and neck cancer of Ho Chi Minh City Oncology Hospital and were treated by radical radiotherapy including interstitial brachytherapy from 01/01/2016 to 01/01/2021. Statistic method were done with SPSS. Result: The optimization objectives for the target volume coverage: the average of D90 = 114% (obtained > 100% prescription dose) and the average of V100 = 96% (obtained > 90% volume). The average D1cc of the mandible was 273cGy, exceeded the designated constraint (≤ 200cGy). Six months after treatment, the frequency of complete response, partial response and progressive disease were 80%, 8% and 12% respectively. The median follow-up time was 13 months. The actuarial 2-year loco-regional control rate was 90%. The complications of interstitial brachytherapy were usually slight and acceptable, bleeding post-implant removal had only 2 cases (8%). Conclusion: The radical radiotherapy, including interstitial brachytherapy, for stage I-III mobile tongue cancers had the good optimization on target volume. The complete response and 2-year locoregional control rate were rather high. The complications of interstitial brachytherapy were usually slight and acceptable.
Article Details
References
2. Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B et al (2001) The American brachytherapy society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int. J. Radiation Oncology Biol. Phys., Elsevier Science Inc., USA 50(5): 1190-1198.
3. Pernot M, Malissart L, Aletti P et al (1992) Iridium-192 brachytherapy in the management of 147 T2N0 oral tongue carcinomas treated with irradiation alone; comparison of two treatment techniques. Radiother Oncol 23: 223-228.
4. Lau HY, Hay JH et al (1996) Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol 39: 15-18.
5. Umeda M, Komatsubara H et al (2005) A comparison of brachytherapy and surgery for the treatment of stage I-II squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg 34: 739-744.
6. Patra NB, Goswami J, Basu S, et al (2009). Outcomes of high dose rate interstitial boost brachytherapy after external beam radiation therapy in head and neck cancer-an Indian learning experience. Brachytherapy 8: 248-254.
Article Sidebar
